Treatment of Morbidly Obese Adolescent With a Duodena-jejunal Liner - a Study on Efficacy and Pathophysiologic Mechanisms

University Medical Centre Ljubljana1 site in 1 country22 target enrollmentJuly 2014

ConditionsObesity Diabetes Metabolic Syndrome

Overview

Phase: Phase 3
Intervention: Not specified
Conditions: Obesity
Sponsor: University Medical Centre Ljubljana
Enrollment: 22
Locations: 1
Primary Endpoint: Change in BMI (BMI SDS)
Status: Completed
Last Updated: 5 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

Obesity and its complications have a significant effect on morbidity and mortality in these subjects. Especially at risk are subjects with extremely increased BMI (above 99th percentile for age and gender in adolescents). In these subjects classical treatment with diet and cognitive therapy has a limited effect. Bariatric procedures, at the moment, are the only feasible therapeutic possibility.

Bariatric procedures are based on several principles; restrictive, malabsorptive and combined. They can be surgical or endoscopic. The later are used in subjects that do not qualify for surgical procedures that decline them or are used before a planed definite bariatric procedure.

Duodena-jejunal liner (DJL) is an endoscopic tool, that is efficiently and safely used to decrease body weight and ameliorated obesity complications, especially those associated with diabetic state.

Aims of the study are:

To determine (short and long-term) efficacy of DJL in decreasing body weight in adolescents.
To determine (short and long-term) efficacy of DJL in ameliorating complications of morbid obesity - abnormal glucose metabolism, dislipidemia, altered adipokine secretion pattern, altered secretion pattern of gastrointestinal hormones in adolescents.
To visualize functional alternations in the selected central nervous system regions associated with appetite regulation upon insertion of DJL.
To evaluate psychological outcomes; change in emotional and behaviour problems, in body image, in eating disorder symptoms.

Registry

clinicaltrials.gov

Start Date

July 2014

End Date

December 20, 2018

Last Updated

5 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

University Medical Centre Ljubljana

Responsible Party

Principal Investigator

Tadej Battelino

Prof. Dr.

University Medical Centre Ljubljana

Eligibility Criteria

Inclusion Criteria

•Subjects estimated to fully comply with study protocol and have signed an informed consent form.
•Age \> 15 years.
•percentile for age and gender.
•Inefficient conservative measures (of at least 6 months duration) to decrease body weight (characterized as a decrease in BMI \> 10 %).
•Documented negative pregnancy test in women of childbearing potential.
•Women of childbearing potential agree to remain on contraceptives for the duration of their trial participation.

Exclusion Criteria

•Previous GI surgery that could potentially affect the ability to place sleeve or affect the function of the implant.
•Subjects with congenital or acquired anomalies of the GI tract which in the opinion of the investigator, may impair implantation of the EndoBarrier device.
•Subjects who had gastrooesophageal reflucs disease..
•Known abnormal pathologies or conditions of the gastrointestinal tract, including ulcers or Crohn's disease, upper gastro-intestinal bleeding conditions.
•Coagulopathy defined as Hgb \<10g/dl and platelet \< 100,000/ml or diagnosis of other severe coagulopathy like hemophilia.
•Any documented history of acute or chronic pancreatitis.
•Subjects requiring regular antithrombotic therapy (i.e. anticoagulant or antiplatelet agent).
•Known diagnosis of systemic lupus erythematosus, scleroderma or other autoimmune connective tissue disorder.
•Subject is or has been enrolled in another investigational study within 6 months of participation into the EndoBarrier study.
•Subjects who are mentally retarded or emotionally unstable.

Outcomes

Primary Outcomes

Change in BMI (BMI SDS)

Time Frame: 12 and 24 months

Secondary Outcomes

Change in basal and stimulated glucose and insulin levels(12 and 24 months)
Change in activity of selected appetite-associated central nervous system regions.(12 and 24 months)
Change in selected adipokine and inflammatory cytokines levels(12 and 24 months)
Change in cholesterol levels(12 and 24 months)
Change in emotional and behaviour problems, body image and eating disorder symptoms(12 and 24 months)
Change in selected gut hormones(12 and 24 months)